This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

Professionals 226 Users Online

Refractory Multiple Myeloma Treatment Market

Refractory Multiple Myeloma Treatment Market - Global Industry Analysis 2014 - 2018 and Forecast 2019 - 2029

Refractory Multiple Myeloma Treatment Market Segmented By Immunomodulatory drugs (IMiDs), Cytotoxic agents, High-Dose Therapy And Autologous Stem Cell Transplantation (HDT-SCT), Allogeneic Stem Cell Transplantation Treatment with Distribution Channel in Hospitals, Cancer Institutes, Ambulatory Surgical Centers

Market Overview

Multiple myeloma is a disorder in malignant plasma cell which mostly affects secondary organs such as bone, renal, bone marrow, immune as well as neurologic dysfunction. Multiple myeloma is a malignancy in clonal plasma cell that results from complex interactions between bone marrow stromal cells, malignant progenitor cells and the bone marrow microenvironment.

Refractory multiple myeloma can be defined as a disease that is progressive or non-responsive on therapy or within sixty days of last treatment in patients with less response. According to Janseen report 2016, an estimate of 38,000 new multiple myeloma cases were recorded each year in Europe. In addition to that, 28% multiple myeloma patients die within a year of diagnosis.

Refractory multiple myeloma treatment is expected to register significant growth in the market owing to increasing prevalence of multiple myeloma, advancement in research and development for innovative therapeutics for the refractory multiple myeloma treatment, introduction of monoclonal antibody for refractory multiple myeloma treatment are some of the factors driving the growth of the refractory multiple myeloma treatment market.

However, currently there is no standard of care for refractory multiple myeloma treatment. Moreover, cost associated with refractory multiple myeloma treatment and huge expenses in research and development in bringing out novel therapeutics may hinder the growth of the refractory multiple myeloma treatment market.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Market Segmentation

Treatment
  • Immunomodulatory drugs (IMiDs)
    • Thalidomide (THAL)
    • Lenalidomide
    • Pomalidomide
    • Bortezomib
    • Carfilzomib
  • Cytotoxic agents
  • High-Dose Therapy And Autologous Stem Cell Transplantation (HDT-SCT)
  • Allogeneic Stem Cell Transplantation
Distribution Channel
  • Hospitals
  • Cancer Institutes
  • Ambulatory Surgical Centers
  • Others
Region
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa
Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

The report covers exhaustive analysis

  • Refractory Multiple Myeloma Treatment Market Segments
  • Refractory Multiple Myeloma Treatment Market Dynamics
  • Historical Actual Market Size, 2014 – 2018ry
  • Refractory Multiple Myeloma Treatment Market Size & Forecast 2019 to 2029
  • Refractory Multiple Myeloma Treatment Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Refractory Multiple Myeloma Treatment Market Drivers and Restraints
Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Report Highlights

  • Shifting Industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size Recent industry trends
  • Key Competition landscape
  • Strategies for key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance
Prerna Shiv

Prerna Shiv
Client Partner

Let's Connect

Conect me to identify wining opportunities

Ask An Expert
I'm Available

- Companies Covered in This Report -

Google translate